A controlled trial of rasagiline in early Parkinson disease: The tempo study

Archives of Neurology

Volumn 59, Issue 12, 2002, Pages 1937-1943

  Siderowf, Andrew ^a   Stern, Matthew ^a   Shoulson, Ira ^b   Kieburtz, Karl ^b   Oakes, David ^b   Day, Denni ^b   Shinaman, Aileen ^b   Plumb, Sandra ^b   Fahn, Stanley ^c   Blindauer, Karen ^d   Lew, Mark ^e   Hurtig, Howard ^a   Lloyd, Mary ^a   Hauser, Robert ^f   Gauger, Lisa ^f   Golbe, Lawrence ^g   Wojcieszek, Joanne ^h   Belden, Joann ^h   Feigin, Andrew ⁱ   Klimek, Mary Lou ⁱ   Shannon, Barbara ⁱ   Ondo, William ^j   Hunter, Christine ^j   Calabrese, Vincent ^k   Atchison, Paul ^l   Allen, Cathy ^l   Marshall, Frederick ^b   Berry, Debra ^b   Gardiner, Irenita ^b   Miyasaki, Janis ^m   Del Rizzo, Luisa ^m   Mendis, Tilak ⁿ   Mendis, Neila ⁿ   Gray, Peggy ⁿ   Hubble, Jean ^o   Betcher, Karen ^o   Pahwa, Rajesh ^p   Molho, Eric ^q   Brown, Diane ^q   Shulman, Lisa ^r   Rajput, Ali ^s   Ewanishin, Marianne ^s   Stacy, Mark ^t   Williamson, Kelli ^t   Bertoni, John ^u   Peterson, Carolyn ^u   Tuite, Paul ^v   Ebbitt, Brenda ^v   Shannon, Kathleen ^w   Jaglin, Jean ^w   Tanner, Caroline ^x   Marek, Kenneth ^y   Stavris, Karen ^y   Aminoff, Michael J ^z   DiMinno, Mariann ^z   Dowling, Glenna ^z   Kang, Un Jung ^aa   Richman, Judy ^aa   Sethi, Kapil ^ab   Martin, Wayne ^ac   King, Pamela ^ac   McInnes, Germaine ^ac   Adler, Charles ^ad   LeWitt, Peter ^ae   DeAngelis, Maryan ^ae   Schear, Myrna ^af   Gordon, Mark Forrest ^ag   Winnick, Roberta ^ag   Feldman, Robert ^ah   Thomas, Cathi Ann ^ah   Conn, Kelly ^b   Brocht, Alicia ^b   Chadwick, Chris ^b   Connolly, Jeannette ^b   Daigneault, Susan ^b   Eberly, Shirley ^b   Bausch, Janice ^b   Josephson, Lee ^b   Oliva, Rosemary ^b   Schwid, Steven ^b   Lang, Anthony ^ai   Cox, Christopher ^b   Irvine, Carrie ^b   Nutt, John ^aj   White, William ^ak   Oren, Sheila ^al   Levy, Ruth ^al   Eyal, Eli ^al   Ladkani, David ^al   Houck, Wayne ^al   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m TORONTO WESTERN HOSPITAL   (Canada)

ⁿ Parkinson's Clinic   (Canada)

^o OHIO STATE UNIVERSITY   (United States)

^p UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^q ALBANY MEDICAL COLLEGE   (United States)

^r UNIVERSITY OF MIAMI   (United States)

^s ROYAL UNIVERSITY HOSPITAL   (Canada)

^t BARROW NEUROLOGICAL INSTITUTE   (United States)

^u CREIGHTON UNIVERSITY   (United States)

^v UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^w RUSH UNIVERSITY MEDICAL CENTER   (United States)

^x PARKINSON S INSTITUTE   (United States)

^y YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa UNIVERSITY OF CHICAGO   (United States)

^ab MEDICAL COLLEGE OF GEORGIA   (United States)

^ac UNIVERSITY OF ALBERTA   (Canada)

^ad MAYO CLINIC   (United States)

^ae Clinical Neuroscience Center   (United States)

^af MOUNT SINAI MEDICAL CENTER   (United States)

^ag LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^ah BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ai UNIVERSITY OF TORONTO   (Canada)

^aj OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ak UNIVERSITY OF CONNECTICUT   (United States)

^al NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE B INHIBITOR; PLACEBO; RASAGILINE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DIVERTICULOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; THORAX PAIN; VERTIGO;

AGED; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0036894795     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.12.1937     Document Type: Article

References (27)

1. Finberg JP, Tenne M, Youdim MB. Tyramine antagonists properties of AGN 1130: An irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981;73:65-74.
2. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-305.
3. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300.
4. Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl. 1998;52:279-285.
5. Marek KL, Friedman J, Hauser R, et al. Phase II evaluation of rasagiline mesylate (TVP-1012), a novel anti-parkinsonian drug, in parkinsonian patients not using levodopa/carbidopa [abstract]. Mov Disord. 1997;12:838.
6. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression, and mortality. Neurology. 1967;17:427-442.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res. 1975;12:189-198.
8. McDermott MP, Jankovic J, Carter J, et al, and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol. 1995;52:565-570.
9. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
10. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
11. Welsh M, McDermott M, Holloway R, et al. Development and testing of the Parkinson's Disease Quality of Life scale: The PDQUALIF [abstract]. Mov Disord. 1997;12:836.
12. Parkinson Study Group. DATATOP: A multi-center controlled clinical trial in early PD. Arch Neurol. 1989;46:1052-1060.
13. Peto R, Pike M, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, I: Introduction and design. Br J Cancer. 1976;34:585-612.
14. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika. 1988;75:800-802.
15. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
16. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
17. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in untreated Parkinson's disease. Ann Neurol. 1993;33:350-356.
18. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopatreated Parkinson's disease. Arch Neurol. 1994;51;342-347.
19. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40:99-107.
20. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology, 1997;49:393-399.
21. Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology. 1997;49:724-728.
22. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. JAMA. 1997;278:125-130.
23. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated P612 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463.
24. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67:577-585.
25. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
26. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116:313-317.
27. Maruyama W, Yamamoto T, Kitani K, Carillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116:181-191.